Zydus Cadila receives final approval from USFDA for Decitabine Injection

Zydus Cadila has received final approval from the USFDA to market Decitabine for Injection in the strength of 50 mg/vial Single-Dose Vial (USRLD: Dacogen). Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer. The drug will be manufactured at the group's injectables manufacturing facility at Zydus Hospira.

The group now has 326 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 463.15 as compared to the previous close of Rs. 472.45. The total number of shares traded during the day was 162777 in over 5263 trades.

The stock hit an intraday high of Rs. 474.65 and intraday low of 461.40. The net turnover during the day was Rs. 75937167.00.

Source : Equity Bulls

Keywords

CadilaHealthcareLimited INE010B01027 CADILAHC Pharmaceuticals Zydus USFDA Approval DecitabineInjection BloodCancer BoneMarrowCancer Injectables